Literature DB >> 3137681

Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in presence of oxidants: a novel principle.

T W Stief1, P Lenz, U Becker, N Heimburger.   

Abstract

A new functional assay of PAI-activity in human plasma is described. Hitherto known assays for fast acting PAI have some disadvantages: predilution and/or acidification steps of the sample to afford the required inactivation of alpha-2-antiplasmin (A2-PI). This approach in contrast implicates test performance in presence of chloramine T (CT), an oxidant that destroys plasma antiplasmin activity without impairing significantly the activity of urokinase (u-PA) or plasmin. The following reaction conditions were found optimal: 50 microliter of undiluted plasma, anticoagulated with citrate or EDTA, were first incubated with 1 IU u-PA in a Tris-buffer, pH 8.4 and then with Glu-plasminogen (0.85 mumol/l final), CT (2.5 mmol/l final), tranexamic acid (0.9 mmol/l final) for 5 min. at 37 degrees C. After addition of 0.3 mmol/l of the chromogenic plasmin substrate H-D-Nva-CHA-Lys-pNA (pNA = para nitroanilide) and of NaCl (250 mmol/l final) a linear kinetic with delta A405/t in the range of 0.2/min for normal plasma was recorded. In an endpoint version of the test the chromogenic substrate can be added together with plasminogen resulting an A/t2-kinetic. Dilution studies showed a linear calibration curve from 0 to 14 arbitrary u-PA inhibiting units (AU)/ml plasma. By means of PAI-standard plasmas PAI-capacity values of 20 healthy volunteers (10 males/10 females) (x = 26 years, sigma = 4.2) were determined. They ranged from 0.4 - 6.9 (x = 1.3, sigma = 0.9) AU/ml plasma. Plasma samples containing more than 14 AU/ml were prediluted with PAI-deficient plasma. Intra- and inter-assay coefficients of variation (CV) were determined to be 1.3 +/- 0.6 and 4.3 +/- 0.5%, respectively. The values of this assay correlate well with those obtained by acidification of the samples. However, the possibility of measuring plasma PAI (and PA) activities by means of a simple and direct approach can be considered as an important progress with regard to routine hospital practice. The presented oxidative inactivation of A2-PI mimics the leukocyte attack phase, suggesting that activated leukocytes create a microenvironment of uncontrolled plasmin activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137681     DOI: 10.1016/0049-3848(88)90204-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine.

Authors:  Thomas Gobbetti; Nicolas Cenac; Jean-Paul Motta; Corinne Rolland; Laurence Martin; Patricia Andrade-Gordon; Martin Steinhoff; Elisabetta Barocelli; Nathalie Vergnolle
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

2.  Hyperfibrinolysis in hepatosplenic schistosomiasis.

Authors:  N E el-Bassiouni; A E el Bassiouny; H R el-Khayat; M M Akl; S A Omran
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

3.  Borrelia burgdorferi induces secretion of pro-urokinase-type plasminogen activator by human monocytes.

Authors:  H Fuchs; M M Simon; R Wallich; M Bechtel; M D Kramer
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

4.  Plasminogen activator inhibitor-1 activity and long-term outcome in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: a prospective cohort study.

Authors:  Marin Pavlov; Vjeran Nikolić-Heitzler; Zdravko Babić; Milan Milošević; Krešimir Kordić; Ivana Ćelap; Vesna Degoricija
Journal:  Croat Med J       Date:  2018-06-30       Impact factor: 1.351

5.  Criteria and Search for Specific Assays for Active Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma.

Authors:  C Kluft
Journal:  EJIFCC       Date:  2000-05-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.